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ESC HOT LINE COMMENTARY
PCI in acute left main disease: a paradigm shift
or a new reality?
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Online publish-ahead-of-print 30 August 2009
This commentary refers to ‘Unprotected left main revas-
cularization in patients with acute coronary syndromes’†,
by G. Montalescot et al., on page 2308
In the last decade, percutaneous coronary intervention (PCI) has
become the treatment of choice for patients with acute coronary
syndrome (ACS) in most industrialized countries. As the benefit of
acute PCI increases with decreasing delay to vessel revasculariza-
tion, major efforts have been focused in optimizing each step in
patient care. This includes raised awareness in the general popu-
lation, well-organized alarm systems, rapid and safe patient trans-
portation, pre-hospital patient care, and centralization of acute
PCI facilities in high-volume centres.1 These optimized strategies
have resulted in a continuous decrease in mortality over the last
few years (Figure 1). In fact, in-hospital mortality after acute PCI
in ACS today is as low as ,5%.2–4 The introduction of new
anti-thrombotics and the increasing use of drug-eluting stents5
have the potential to improve the outcome of ACS patients
further. In addition, elective revascularization of left main disease
exhibited very promising results in recent trials. In the subgroup
of patients with relevant left main disease of the recently published
SYNTAX trial, rates for major adverse cardiac or cerebrovascular
events were similar in patients treated with PCI and coronary
artery bypass graft (CABG) (15.9 and 13.7%, respectively).6
However, left main stenting has been carried out with increasing
frequency during the last years. Nevertheless, patients with unpro-
tected left main disease still represent a challenge for the interven-
tionalist, especially in the setting of an ACS.
Montalescot et al. have reported the results of patients with
ACS and left main disease included in the Global Registry of
Acute Coronary Events (GRACE) between 2000 and 2007.7
From a total of 43 018 patients, 1799 patients (4%) with relevant
left main disease were treated by either PCI alone (n ¼ 514),
CABG alone (n ¼ 612), or no revascularization (n ¼ 673). Over
time, a trend towards more PCI and less CABG was observed.
Several pieces of important information can be derived from this
study. First of all, unprotected left main disease in patients with
ACS is associated with a high mortality, especially in patients
presenting with ST-segment elevation myocardial infarction
(STEMI) and/or haemodynamic instability. Overall in-hospital mor-
tality was 7.7%, but reached 11% in patients who presented with
STEMI or new left bundle branch block (LBBB), and was as high
as 34% in patients with cardiogenic shock or cardiac arrest. For
comparison, in the recently published Expanded GRACE registry,4
in-hospital mortality was 3.7%. The second important piece of
information is that in patients not requiring immediate revascular-
ization, a postponed surgical revascularization (during the same
hospitalization) provides the best short- and long-term outcome.
Patients treated with CABG had an in-hospital mortality of 5.4%,
which favourably compared with patients treated conservatively
(7.6%) or by PCI (11%). As this is a register and not a randomized
trial, we cannot conclude that one or the other revascularization
strategies provides better outcome. Patients treated with acute
PCI did indeed present more often as STEMI, new LBBB, or cardio-
genic shock. Thus, patients treated with PCI had the highest risk at
hospital admission. This explains the high in-hospital mortality in
this group, but also the incremental mortality of 5.4% during the
next months (i.e. between hospital discharge and 6-months
follow-up). The good results seen with CABG are at least in part
due to a lower risk for this patient group at admission and a
patient selection bias. In fact, median time from admission to oper-
ation was 4.5 days. Hence, patients who were initially scheduled for
CABG, but died before the operation were assigned to the ‘con-
servative treatment group’. This selection bias is also important
in patients with previous cardiac arrest where the neurological
condition often only becomes evident after 1 or 2 days. Neverthe-
less, the outcome of patients treated with CABG was excellent,
with incremental mortality of only 1.6% at 6 months. Patients
with initial conservative treatment, on the other hand, exhibited
an in-hospital mortality of 7.6%. Although 39% of these patients
were scheduled for elective CABG, the mortality rate between
hospital discharge and 6-month follow-up was as high as 10%. In
fact, it appears that the third and probably most relevant
message from this registry is that patients that were revascularized
during the event hospitalization showed a better long-term
outcome compared with the initial conservative therapy. This
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highlights the importance of early revascularization in the presence
of symptomatic left main disease.
As mentioned above, it is important to keep in mind that these
data were derived from a registry and not a randomized study.
Thus, the presence of selection bias is evident and is reflected
by the differences in clinical presentation. In addition, left main
disease is a very heterogenous disease in terms of clinical presen-
tation and anatomy, and each factor can potentially influence the
decision-making process in the setting of ACS. A complete occlu-
sion of the left main, for instance, is usually associated with cardio-
genic shock and therefore represents a very high-risk situation
requiring immediate life support strategies and urgent revasculari-
zation, often in conjunction with the use of left ventricle assist
devices, whereas a subtotal stenosis may present as unstable
angina with subendocardial ischaemia associated with a much
lower risk. For the interventionalist, an ostial or midshaft left
main lesion is easier to treat than distal lesions (which normally
represent a real technical challenge because of the involvement
of a major vessel bifurcation). In addition to lesion morphology,
several clinical features might influence decision-making strategies.
Indeed, the presence of three-vessel disease or a total occlusion of
the right coronary artery may shift the treatment preference of the
physician in charge towards surgical revascularization. In contrast,
patients presenting with haemodynamic or rhythm instability
require immediate decision making, resulting most commonly in
an urgent percutaneous revascularization. Even though the
optimal treatment strategy for an individual patient can be
reached in a case-based discussion between interventionalist and
cardiac surgeon, such an approach is not applicable in an emer-
gency situation. This explains why it is indeed very difficult to
conduct a randomized trial in patients with ACS and left main
disease. Nevertheless, as demonstrated by the SYNTAX trial,
such studies are possible under certain conditions. In patients pre-
senting with ACS, however, only those in haemodynamically stable
conditions may be eligible for future trials. Such a study would be
important, as suggested by the registry data of Montalescot et al.7
Finally, a concern of this study may be the short follow-up (6
months). Unplanned revascularization due to instent-restenosis and
late/very late stent thrombosis may affect the long-term outcome of
PCI patients and favour surgical revascularization in the long term.
Currently, rates of target lesion revascularization in patients with left
main disease receiving a drug-eluting stent range from 0 to 14%.8
In our opinion, this observational study provides new important
data that stress the importance of prompt and complete revascu-
larization of patients presenting with ACS and left main coronary
artery disease. Further research is required to characterize
better those patients which benefit the most from percutaneous
or surgical revascularization.
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